Research

The department has a number of methodological research interests and our members are engaged in a broad range of collaborative projects. The main research areas are summarised below.

  • Clinical trials and Methodology Research

    open-content-icon

    The Clinical Trials Research Centre (CTRC) provides a support and advice service to NHS professionals and academic researchers for NHS research. CTRC supports phase I - IV multi centre randomised controlled trials, systematic reviews, core outcome sets, service evaluation and other research. CTRC is part of the Liverpool Trials Collaborative, which is fully registered with the UKCRC.

    Visit the CTRC website for further information.

    The MRC North West Hub for Trials Methodology Research (NWHTMR) aims to facilitate and accelerate the translational process through the development of new and improved approaches for the design, conduct and analysis of clinical trials, particularly in methodologically challenging areas. 


    The MRC NWHTMR is a collaboration between the Universities of Liverpool, Lancaster, Bangor and Manchester, involving experts in medical statistics, clinical trial methodology, pharmacoeconomics, sociology and clinical psychology.

    Visit the MRC NWHTMR website for further information.

    Or contact Professor Paula Williamson, Professor Catrin Tudur Smith or Professor Carrol Gamble.

  • Evidence Synthesis

    open-content-icon

    Areas of particular interest are Issues surrounding meta-analyses of Individual Patient Data, Within-study selective reporting bias, Dealing with missing data at the patient level including issues around non intention to treat analysis, Publication bias, Comparing individual patient data and aggregate data meta-analyses, Meta-analysis of method comparison studies, Meta-analysis of longitudinal data, Meta-analysis of time-to-event data.

    For further information, contact Professor Catrin Tudur Smith

  • Health Informatics

    open-content-icon

    For further information, contact Dr Keith Bodger or visit the Health Data Science Network

  • Statistical Modelling

    open-content-icon

    Emerging data collection protocols in clinical research introduce complexities, which are either not covered by existing generally available software, or more fundamentally, require further statistical methodological development. The Department accommodates several inter-linked research groups with interests on methodologies and software of Multivariate data modelling, Joint longitudinal and event history modelling, Statistical Genetics and Pharmacogenomics, Prognostic modelling and Causal analysis.

    Multivariate data modelling

    Multivariate data modelling is often applied to address research questions such as ‘are there a small number of underlying factors explaining the variables in the dataset?’, ‘is there a natural clustering in the dataset?’, ‘can we classify individuals into groups based on their characteristics?’ or ‘can we predict that a person will develop a particulr condition/disease by looking at a range of symptoms?’

    The multivariate modelling research group has expertise in multivariate methodologies, their application to clinical data, and the development of software in R and in other statistical packages. The group aims to develop methodologies and disseminate concepts among researchers and clinicians.

    Commonly applied multivariate techniques are discriminant function analysis, cluster analysis, principal components analysis, factor analysis, multidimensional scaling and MANOVA amongst others.

    For further information, contact Dr Marta Garcia-Finana or visit Liverpool multivariate modeling group website


    Joint longitudinal and event history modelling

    Often in health research, patients are followed-up over time to monitor the progression of a disease as it develops using some biomarkers. Hence, the need for joint modelling of combined longitudinally repeated measurements and event-time data to investigate how the patterns over time in biomarkers relate to prognosis for the patient, and in particular to the timing of clinically significant events. However, a major difficulty is how best to merge information from the longitudinally repeated measurements and event history data, especially as the longitudinal data is usually irregularly and imperfectly observed.

    Further, although longitudinal data are prevalent throughout the medical literature, joint modelling methods are not routinely used. Often, simpler approaches are used, for example separate analyses of longitudinal and event-time data, because of the ready availability of standard software. These methods potentially suffer from inefficiency or, worse, severe bias through misspecification, for example by failing to take account of informative dropout during the intended follow-up period.

    The JoineR collaboration involves (1) Development of novel statistical methods for the analysis of complex longitudinal data structures, (2) Implementation of user-friendly software for new statistical methods, and (3) Dissemination of the modern methods of statistical analysis to the medical research community.

    For further information, contact Dr Ruwanthi Kolamunnage-Dona or visit Joint modelling group website


    Statistical Genetics and Pharmacogenomics

    The Statistical Genetics and Pharmacogenomics Research Group focus on developing, evaluating and applying methodology for the analysis of genome-wide association (GWA) and re-sequencing studies of complex human traits, with a particular focus on type 2 diabetes and related metabolic traits, women’s health disorders and response to pharmaceutical drugs (efficacy and adverse events).

    Key themes of our research include: aggregating GWA studies from diverse populations through trans-ethnic meta-analysis; modelling of multiple correlated traits; analysis of rare variants in gene-based analyses of time-to-event outcomes; evidence synthesis for pharmacogenetic studies.

    The findings of our research will contribute to evaluating the utility of GWA studies of common and rare genetic variation for complex trait gene mapping, and will ultimately provide a more comprehensive view of the genetic architecture of common human diseases and drug response.

    For further information, contact Dr Andrea Jorgensen, Professor Andrew Morris or visit Statistical Genetics and Pharmacogenomics Research Group website


    Prognostic modelling

    Prognosis research provides information crucial to understanding, explaining and predicting future clinical outcomes in people with existing disease or health conditions.  In particular, clinical prediction models estimate the risk of existing disease (diagnostic prediction model) or future outcome (prognostic prediction model) for an individual, conditional on their values of multiple predictors (prognostic or risk factors) such as age, sex and biomarkers.

    A large number of prediction models are published in the medical literature each year, and most are developed using a regression framework such as logistic and Cox regression. Prediction models are also known as risk scores, prognostic indices, or prognostic scores.

    The prognosis research group is focussed on (1) Development and validation (both internal and external) methodologies of prognostic models, (2) Extending areas of clinical application, and (3) Disseminating concepts among researchers and healthcare professionals. The group has expertise in the development of software in R language and in other statistical packages, as well as presentation formats based on stakeholder engagement.

    For further information, contact Dr Laura Bonnett


    Causal analysis

    Nonadherence is common in general medical practice and trials, with huge economic and clinical consequences. Nonadherence complicates trial analysis and interpretation, as the underlying random assignment mechanism, which forms the basis for unbiased hypothesis testing, no longer reflects treatment received.

    In the presence of deviations from randomised treatment, an intention to treat (ITT) analysis only provides an estimate of the policy of prescribing treatment, rather than of the efficacy of treatment actually received.  Regulatory and funding bodies are increasingly recognising the importance of considering adherence in trial efficacy analyses, with growing awareness of appropriate statistical causal methodologies which seek to overcome selection biases associated with simple methods such as per protocol analysis. However, such methodologies are not commonly used in trial settings, as they are unfamiliar to trial statisticians and tend to be more complex and computationally intensive than simpler methods.

    The causal analysis research group is involved in 1) Application of causal methodologies in randomised trials, 2) Implementation of user-friendly analysis tools to make causal analysis methods easily accessible to trial statisticians and 3) Development of novel methodologies to obtain accurate adherence information to inform causal analyses.

    For further information, contact Dr Susanna Dodd.